Innovent registers Phase 3 trial comparing IBI3027 to dupilumab in atopic dermatitis
A new Phase 3 study will test whether IBI3027 performs equivalently to Dupilumab Injection in patients with moderate to severe atopic dermatitis.
Innovent Biologics (Suzhou) Co. Ltd. has one trial update of note this week.
- This Phase 3, multicenter, randomized study is recruiting participants to compare IBI3027 against Dupilumab Injection in moderate to severe atopic dermatitis. The study plans to enroll about 520 patients, who will be split evenly between an IBI3027 treatment group and a Dupilumab Injection control group.1 The trial's primary outcome is the proportion of participants who achieved EASI-75, measured at Week 16.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.